For research use only. Not for therapeutic Use.
Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent[1].
Tofisopam administration at a dose of 50 mg/kg for seven days improves the impaired cognitive performance, enhances the attenuated synaptic transmission in the hippocampus, increases proliferation in subgranular zones, and improves the decrease in astrocytes in amnesic rats[1].
| Catalog Number | I009767 |
| CAS Number | 22345-47-7 |
| Synonyms | 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine |
| Molecular Formula | C22H26N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3 |
| InChIKey | RUJBDQSFYCKFAA-UHFFFAOYSA-N |
| SMILES | CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C |
| Reference | [1]. Umut İrfan Üçel, et al. Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats. Pharmacol Biochem Behav. 2020 Mar;190:172858. |
